![Laura Cassin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Laura Cassin
Analyste en capital-investissement chez
Nimbus Synergies, Inc.
Profil
Laura Cassin is an Investment Analyst at Nimbus Synergies, Inc. since 2017.
She completed her undergraduate degree from the University of Victoria in 1998.
Postes actifs de Laura Cassin
| Sociétés | Poste | Début |
|---|---|---|
Nimbus Synergies, Inc.
 Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices. | Analyste en capital-investissement | 01/06/2017 |
Formation de Laura Cassin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
77
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
University of Victoria
 University of Victoria Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nimbus Synergies, Inc.
Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices. | Finance |
